Aeglea Bio Therapeutics (NASDAQ: AGLE) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Aeglea Bio Therapeutics to related companies based on the strength of its earnings, profitability, institutional ownership, analyst recommendations, valuation, risk and dividends.
Institutional & Insider Ownership
46.9% of Aeglea Bio Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 27.0% of Aeglea Bio Therapeutics shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
Aeglea Bio Therapeutics has a beta of 2.66, indicating that its stock price is 166% more volatile than the S&P 500. Comparatively, Aeglea Bio Therapeutics’ competitors have a beta of 0.49, indicating that their average stock price is 51% less volatile than the S&P 500.
This table compares Aeglea Bio Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aeglea Bio Therapeutics||-527.99%||-44.05%||-41.00%|
|Aeglea Bio Therapeutics Competitors||-5,277.49%||-435.66%||-39.69%|
Valuation & Earnings
This table compares Aeglea Bio Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aeglea Bio Therapeutics||$4.63 million||-$21.69 million||-2.68|
|Aeglea Bio Therapeutics Competitors||$284.28 million||$34.29 million||133.28|
Aeglea Bio Therapeutics’ competitors have higher revenue and earnings than Aeglea Bio Therapeutics. Aeglea Bio Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings for Aeglea Bio Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aeglea Bio Therapeutics||0||0||0||0||N/A|
|Aeglea Bio Therapeutics Competitors||851||3198||11598||231||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.65%. Given Aeglea Bio Therapeutics’ competitors higher probable upside, analysts plainly believe Aeglea Bio Therapeutics has less favorable growth aspects than its competitors.
Aeglea Bio Therapeutics competitors beat Aeglea Bio Therapeutics on 5 of the 9 factors compared.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.
Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.